Select the option that best describes what you are looking for
Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.
Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.
Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.
Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.
Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.
Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.
Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.
Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.
Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.
Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.
Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.
Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.
Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.
Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.
Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.
Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.
Certified CRO services with NanoString GeoMx Digital Spatial Profiling.
De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.
Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.
Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.
Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.
Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.
Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.
Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.
Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.
Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.
We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.
We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.
Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.
Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.
Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.
Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.
Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.
Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.
The MuScreen platform is the first high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (MuPrime™) models.
This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development.
Choose MuScreen to:
Model Type | Model Features | Efficacy | PD | ||
---|---|---|---|---|---|
US | China | US | China | ||
Syngeneic | Display immune heterogeneity and diversity observed in the clinic |
6 models |
12 models |
6 models |
12 models |
Tumor Homograft | Transplants of GEMM tumors into a syngeneic host, preserving original GEMM tumor molecular and histopathology and clinically relevant oncogenic driver mutations |
6 models |
Registration Deadline | Study Initiation |
---|---|
January 12th, 2024 | March 1st, 2024 |
April 19th, 2024 | May 17th, 2024 |
July 12th, 2024 | August 9th, 2024 |
September 13th, 2024 | October 18th, 2024 |
Registration Deadline | Study Initiation |
---|---|
January 12th, 2024 | March 1st, 2024 |
April 19th, 2024 | May 17th, 2024 |
July 12th, 2024 | August 9th, 2024 |
September 13th, 2024 | October 18th, 2024 |
Registration Deadline | Study Initiation |
---|---|
January 12th, 2024 | March 1st, 2024 |
May 10th, 2024 | June 21st, 2024 |
September 6st, 2024 | October 18th, 2024 |
Choose between 6 or 12 well-characterized syngeneic models to evaluate your I/O compound efficacy or PD effect.
Cancer Type | Model | Mouse Strain | Immune Cell Profiling | RNAseq | Baseline Proteomics Data |
---|---|---|---|---|---|
Breast | EMT6* | BALB/c | Yes | Yes | Yes |
Bladder | MB49 | C57BL/6 | Yes | Yes | No |
Colorectal | CT26.WT* | BALB/c | Yes | Yes | Yes |
MC38 | C57BL/6 | Yes | Yes | Yes | |
Kidney | Renca | BALB/c | Yes | Yes | Yes |
Liver | H22^ | BALB/c | Yes | Yes | Yes |
Hepa 1-6 | C57BL/6 | Yes | Yes | Yes | |
Lung | LL/2 | C57BL/6 | Yes | Yes | Yes |
Lymphoma | A20* | BALB/c | Yes | Yes | Yes |
Melanoma | B16-F10* | C57BL/6 | Yes | Yes | Yes |
Pancreatic | Pan02* | C57BL/6 | Yes | Yes | Yes |
Prostate | RM-1* | C57BL/6 | Yes | Yes | Yes |
* Models are run at our US site in a 6 model MuScreen
^ This line is not applicable for FACS
Syngeneic models display immune heterogeneity and diversity observed in the clinic, enabling comprehensive evaluation of efficacy and PD effects of your immune modulating agents.
Key advantages of syngeneic models include:
Our syngeneic models are highly characterized, with data including:
Visit MuBase® for all available model data
Test your I/O agent antitumor efficacy in vivo on a panel of our unique tumor homograft models
Cancer Type | Model | Mutations/Carcinogen | Strain Background |
Immune Profiling |
RNAseq | Growth Curve |
SoC Data |
---|---|---|---|---|---|---|---|
Breast | mBR6004 | MMTV-PyVT TG | FVB/N | Yes | Yes | Yes | Yes |
Liver | mLI9040 | Alb-Cre; CAG-LSL-cMyc | C57BL/6 | Ongoing | Yes | Yes | Yes |
Lung | mLU6045 | Kras(G12D); P53-/- | C57BL/6 | Yes | Yes | Yes | Yes |
Pancreatic | mPA6115 | Kras(G12D); P53-/-; PDx-1 cre | C57BL/6 | Yes | Yes | Yes | Yes |
Sarcoma | mSA9003 | P53-/- | C57BL/6 | Yes | Yes | Yes | Yes |
Skin | mSK6005 | ApcMin/+ | C57BL/6 | Yes | Yes | Yes | Yes |
Tumor homografts are transplants of spontaneous or carcinogen-induced GEMM tumors in immunocompetent syngeneic hosts. They preserve the original GEMM tumor molecular and histopathology as well as clinically relevant oncogenic driver mutations.
Our MuPrime tumor homografts have been developed to broaden the number and molecular pathology of preclinical syngeneic models for in vivo pharmacology studies.
Key advantages of MuPrime tumor homografts include:
Our tumor homograft models are well characterized with available characterization data including:
Visit MuBase for all available model data
MuScreen Efficacy and PD Mode are run following a preset schedule along with a shared vehicle group.
The main study endpoint for the efficacy mode is Tumor Growth Inhibition (TGI) with optional terminal Mouse I/O RNA-Seq Panel readout, FACS and IHC.
In the PD mode, choose between FACS analysis of tumor infiltrating lymphocytes and tumor associated macrophages at selected time points, and Mouse I/O RNA-Seq Panel which comprehensively profiles 1080 genes associated with tumor immunity, as your main endpoint. Additional endpoints include cytokine panel profiling in blood and tumor, IHC for biomarker analysis on tumor tissues, blood cells, lymph nodes, and spleen cells.
Frozen or fixed tumors are available on request for both modes.
Find the best models for the preclinical evaluation of your immuno-oncology agent by logging on to Crown Bioscience’s searchable database of well-characterized and validated mouse models. Crown Bioscience offers a wide selection of murine research models including syngeneic, tumor homograft (MuPrime), GEMM, and humanized drug target (HuGEMM) models to screen your compounds of interest.
Access MuBase to explore genomic, molecular, and phenotypic data including tumor growth curves, standard of care response, histopathology data, and immune cell profiling data on this wide collection of immuno-oncology mouse models.
Browse, search, and stratify across different model types
Review treatment data for specific models including immune checkpoint inhibitors
Interested in enrolling your Immuno-Oncology Agents? or have more questions?
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-10-18
2021-10-22
site_page